Although our findings showed no increase in FASN mRNA levels in de novo ALL patients compared with the control group, FASN showed significant upregulation in positive MRD patients known as drug resistant group compared with the drug sensitive or MRD− group. This evidence concerns the gene FASN and acute lymphoblastic leukemia.